entertainment -WSS

entertainment

author：comprehensive 2025-09-02 11:47:03 - browse：93368

Illumina, the largest maker of DNA-sequencing technology and a storied name in the biotechnology industry, named Jacob Thaysen, a 10-year-veteran at life sciences-tools firm Agilent, as its new CEO.

The appointment follows a bitter board fight that ended with the departure of Francis deSouza, who had been Illumina’s CEO since 2016. The battle, tipped off by Illumina’s troubled acquisition of cancer diagnostics firm Grail, had involved a proxy fight staged by activist investor Carl Icahn.

During the battle, there had been speculation that Jay Flatley, deSouza’s predecessor, could return. Under Flatley, Illumina had grown from an upstart to the dominant player in a field that has proved pivotal for medical research and delivered sizable returns to investors.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Alkermes shareholders re
Next article： Deposition: Sackler embraced plan to conceal OxyContin’s strength

focus

WSS

Cheap, fast test for Zika and dengue could cost just $1

Judge rejects Trump's request to move Stormy Daniels hush

Indian pharmaceutical industry in denial over drug

Vir antibody drug aimed at influenza A fails in clinical trial

Vir antibody drug aimed at influenza A fails in clinical trial

Vir antibody drug aimed at influenza A fails in clinical trial

focus

entertainment

hotspot

ChatGPT in medicine: STAT answers readers' burning questions

Awakening the world to the whoosh: A patient's crusade

Affirmative action in medical school literally saved lives

Stanford president faces new allegations over 1999 paper

Hepatitis C has a cure — but many Americans still lack access to it

Mass General totes up its waste in a move to tackle climate change

23andMe had bad news about my health. I wish a person had delivered it

Coercive sterilizations revealed by STAT prompt outrage

United colonoscopy coverage change 'may cost lives,' doctors say

Medical device trials still don't enroll enough women, study finds

focus

Stephen Quake on the Chan Zuckerberg quest to conquer disease

Tocagen's brain cancer gene therapy trial continues. Investors worry

FDA reviewers ask if approval of Lilly’s Alzheimer’s drug should be restricted

A Q&A with Gavi’s Seth Berkley on vaccines, Covid, and more

Cigna wins case to block Amy Bricker's move to CVS

Stanford president faces new allegations over 1999 paper

explore

hotspot

focus

hotspot